Pharmacokinetic Comparison of XS003 and Tasigna

Status:
Completed

Trial end date:
2014-05-01

Target enrollment:

Participant gender:

The study will assess bioavailability of XS003 given as a single oral dose compared to Tasigna® given as a single oral dose in healthy male subjects.

Phase 1

XSpray Microparticles